Literature DB >> 7620718

Effects of tyrosine kinase inhibitors on the contractility of rat mesenteric resistance arteries.

C Toma1, P E Jensen, D Prieto, A Hughes, M J Mulvany, C Aalkjaer.   

Abstract

1. A pharmacological characterization of tyrosine kinase inhibitors (TKI) belonging to two distinct groups (competitors at the ATP-binding site and the substrate-binding site, respectively) was performed, based on their effects on the contractility of rat mesenteric arteries. 2. Both the ATP-site competitors (genistein and its inactive analogue, daidzein) and the substrate-site competitors (tyrphostins A-23, A-47 and the inactive analogue, A-1) reversibly inhibited noradrenaline (NA, (10 microM)) and KCl (125 mM) induced contractions, concentration-dependently. Genistein was slightly but significantly more potent than daidzein; the tyrphostins were all less potent than genistein, and there were no significant differences between the individual potencies. The tyrosine kinase substrate-site inhibitor bis-tyrphostin had no inhibitory effect. 3. Genistein, daidzein, A-23 and A-47 each suppressed the contraction induced by Ca2+ (1 microM) in alpha-toxin permeabilized arteries. A-1 and bis-tyrphostin had little or no effect on contraction of the permeabilized arteries. 4. Genistein was significantly more potent than daidzein with respect to inhibition of the contraction induced by 200 nM Ca2+ in the presence of NA (100 microM) and GTP (3 microM). The effect of A-23, A-47, A-1 and bis-tyrphostin was similar in permeabilized arteries activated with Ca2+ (200 nM) + NA (100 microM) + GTP (3 microM) and permeabilized arteries activated with 1 microM Ca2+. 5. Genistein (30 microM) reduced the fura-2 measured intracellular calcium activity ([Ca2+]j) in arteries stimulated with NA but had no effect on [Ca2+]i in arteries stimulated with KCl (125 mM).6. The potent effect of the TKIs in this study is consistent with a role for tyrosine kinases in the mechanisms which regulate both cytoplasmic Ca2+ levels and the effect of Ca2+ on the contractile apparatus in smooth muscle cells in resistance arteries. However, the results must be interpreted cautiously because the enzyme inhibitors may have a poor specificity in intact tissues and because the presumed inactive analogues had potent effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620718      PMCID: PMC1510337          DOI: 10.1111/j.1476-5381.1995.tb13342.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Focal adhesion kinase: an integrin-linked protein tyrosine kinase.

Authors:  M D Schaller; J T Parsons
Journal:  Trends Cell Biol       Date:  1993-08       Impact factor: 20.808

2.  Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells.

Authors:  S Wijetunge; C Aalkjaer; M Schachter; A D Hughes
Journal:  Biochem Biophys Res Commun       Date:  1992-12-30       Impact factor: 3.575

Review 3.  Tyrosine-phosphorylated proteins: mediators of signal transduction from the tyrosine kinases.

Authors:  J R Glenney
Journal:  Biochim Biophys Acta       Date:  1992-03-16

Review 4.  Protein kinase inhibitors: probes for the functions of protein phosphorylation.

Authors:  J E Casnellie
Journal:  Adv Pharmacol       Date:  1991

Review 5.  Tyrphostins as molecular tools and potential antiproliferative drugs.

Authors:  A Levitzki; C Gilon
Journal:  Trends Pharmacol Sci       Date:  1991-05       Impact factor: 14.819

Review 6.  The molecular genetics of cancer.

Authors:  J M Bishop
Journal:  Science       Date:  1987-01-16       Impact factor: 47.728

7.  Tyrosine kinase inhibitors suppress agonist-induced contraction in smooth muscle.

Authors:  J Di Salvo; A Steusloff; L Semenchuk; S Satoh; K Kolquist; G Pfitzer
Journal:  Biochem Biophys Res Commun       Date:  1993-02-15       Impact factor: 3.575

8.  Genistein, a specific inhibitor of tyrosine-specific protein kinases.

Authors:  T Akiyama; J Ishida; S Nakagawa; H Ogawara; S Watanabe; N Itoh; M Shibuya; Y Fukami
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

9.  Distinct signal transduction pathways for angiotensin-II in guinea pig gastric smooth muscle: differential blockade by indomethacin and tyrosine kinase inhibitors.

Authors:  S G Yang; M Saifeddine; A Laniyonu; M D Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  1993-02       Impact factor: 4.030

10.  Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s).

Authors:  M D Sauro; B Thomas
Journal:  J Pharmacol Exp Ther       Date:  1993-12       Impact factor: 4.030

View more
  9 in total

1.  Effect of acute and long-term treatment with 17-beta-estradiol on the vasomotor responses in the rat aorta.

Authors:  H L Andersen; J U Weis; B Fjalland; N Korsgaard
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

2.  The vascular activity of some isoflavone metabolites: implications for a cardioprotective role.

Authors:  J P Chin-Dusting; L J Fisher; T V Lewis; A Piekarska; P J Nestel; A Husband
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

3.  Mechanism of action of angiotensin II in human isolated subcutaneous resistance arteries.

Authors:  R S Garcha; P S Sever; A D Hughes
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  The flavonoid scaffold as a template for the design of modulators of the vascular Ca(v) 1.2 channels.

Authors:  S Saponara; E Carosati; P Mugnai; G Sgaragli; F Fusi
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 5.  Smooth muscle contractility and protein tyrosine phosphorylation.

Authors:  A K Srivastava; J St-Louis
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

Review 6.  Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors.

Authors:  Elfaridah P Frazier; Stephan L M Peters; Alan S Braverman; Michael R Ruggieri; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-04       Impact factor: 3.000

Review 7.  Specialized Functional Diversity and Interactions of the Na,K-ATPase.

Authors:  Vladimir V Matchkov; Igor I Krivoi
Journal:  Front Physiol       Date:  2016-05-25       Impact factor: 4.566

8.  Translational value of mechanical and vasomotor properties of mouse isolated mesenteric resistance-sized arteries.

Authors:  Emilie M Outzen; Marina Zaki; Bahareh Abdolalizadeh; Anette Sams; Harrie C M Boonen; Majid Sheykhzade
Journal:  Pharmacol Res Perspect       Date:  2015-12-22

9.  The Na,K-ATPase-Dependent Src Kinase Signaling Changes with Mesenteric Artery Diameter.

Authors:  Lin Zhang; Christian Aalkjaer; Vladimir V Matchkov
Journal:  Int J Mol Sci       Date:  2018-08-23       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.